Ontology type: schema:ScholarlyArticle
2019-02
AUTHORST. R. Jeffry Evans, Emma Dean, L. Rhoda Molife, Juanita Lopez, Malcolm Ranson, Fatima El-Khouly, Ishtiaq Zubairi, Claudio Savulsky, Larisa Reyderman, Yan Jia, Lorna Sweeting, Alastair Greystoke, Jorge Barriuso, Rebecca Kristeleit
ABSTRACTBACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours. METHODS: Eligible patients with ECOG PS 0-1 were treated with eribulin-LF either on day 1 every 21 days (Schedule 1), or on days 1 and 15 every 28 days (Schedule 2). Doses ranged from 1.0 to 3.5 mg/m2, with dose escalation in a 3 + 3 design. The dose-expansion phase evaluated eribulin-LF in select tumour types. PRIMARY OBJECTIVES: maximum tolerated dose (MTD) and the recommended dose/schedule of eribulin-LF. RESULTS: Totally, 58 patients were enroled (median age = 62 years). The MTD was 1.4 mg/m2 (Schedule 1) or 1.5 mg/m2 (Schedule 2), the latter dose selected for the dose-expansion phase. Dose-limiting toxicity (DLTs) in Schedule 1: hypophosphatemia and increased transaminase levels. DLTs in Schedule 2: stomatitis, increased alanine aminotransferase, neutropenia and febrile neutropenia. The pharmacokinetic profile of eribulin-LF showed a similar half-life to that of eribulin (~30 h), but with a 5-fold greater maximum serum concentration and a 40-fold greater area-under-the-curve. Eribulin-LF demonstrated clinical activity with approximately 10% of patients in both schedules achieving partial responses. CONCLUSIONS: Eribulin-LF was well tolerated with a favourable pharmacokinetic profile. Preliminary evidence of clinical activity in solid tumours was observed. More... »
PAGES379-386
http://scigraph.springernature.com/pub.10.1038/s41416-019-0377-x
DOIhttp://dx.doi.org/10.1038/s41416-019-0377-x
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1111642723
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/30679780
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "University of Glasgow",
"id": "https://www.grid.ac/institutes/grid.8756.c",
"name": [
"Beatson West of Scotland Cancer Centre, Glasgow, UK",
"University of Glasgow, Glasgow, UK"
],
"type": "Organization"
},
"familyName": "Evans",
"givenName": "T. R. Jeffry",
"id": "sg:person.013162613642.37",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013162613642.37"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Christie Hospital NHS Foundation Trust",
"id": "https://www.grid.ac/institutes/grid.412917.8",
"name": [
"The Christie NHS Foundation Trust, Manchester, UK"
],
"type": "Organization"
},
"familyName": "Dean",
"givenName": "Emma",
"id": "sg:person.01041560063.08",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041560063.08"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Royal Marsden NHS Foundation Trust",
"id": "https://www.grid.ac/institutes/grid.5072.0",
"name": [
"The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, UK"
],
"type": "Organization"
},
"familyName": "Molife",
"givenName": "L. Rhoda",
"id": "sg:person.01176172571.54",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176172571.54"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Royal Marsden NHS Foundation Trust",
"id": "https://www.grid.ac/institutes/grid.5072.0",
"name": [
"The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, UK"
],
"type": "Organization"
},
"familyName": "Lopez",
"givenName": "Juanita",
"id": "sg:person.014561733511.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014561733511.48"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Christie Hospital NHS Foundation Trust",
"id": "https://www.grid.ac/institutes/grid.412917.8",
"name": [
"The Christie NHS Foundation Trust, Manchester, UK"
],
"type": "Organization"
},
"familyName": "Ranson",
"givenName": "Malcolm",
"id": "sg:person.01124372241.32",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124372241.32"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "University College London",
"id": "https://www.grid.ac/institutes/grid.83440.3b",
"name": [
"UCL Cancer Institute, London, UK"
],
"type": "Organization"
},
"familyName": "El-Khouly",
"givenName": "Fatima",
"id": "sg:person.01274610707.71",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274610707.71"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Beatson West of Scotland Cancer Centre",
"id": "https://www.grid.ac/institutes/grid.422301.6",
"name": [
"Beatson West of Scotland Cancer Centre, Glasgow, UK"
],
"type": "Organization"
},
"familyName": "Zubairi",
"givenName": "Ishtiaq",
"id": "sg:person.07545311260.46",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07545311260.46"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Eisai (United Kingdom)",
"id": "https://www.grid.ac/institutes/grid.428696.7",
"name": [
"Eisai Ltd., Hatfield, UK"
],
"type": "Organization"
},
"familyName": "Savulsky",
"givenName": "Claudio",
"id": "sg:person.011515070473.83",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011515070473.83"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Eisai (United States)",
"id": "https://www.grid.ac/institutes/grid.418767.b",
"name": [
"Eisai Inc., Woodcliff Lake, NJ, USA"
],
"type": "Organization"
},
"familyName": "Reyderman",
"givenName": "Larisa",
"id": "sg:person.0627241052.36",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627241052.36"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Eisai (United States)",
"id": "https://www.grid.ac/institutes/grid.418767.b",
"name": [
"Eisai Inc., Woodcliff Lake, NJ, USA"
],
"type": "Organization"
},
"familyName": "Jia",
"givenName": "Yan",
"id": "sg:person.07520112340.26",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07520112340.26"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Beatson West of Scotland Cancer Centre",
"id": "https://www.grid.ac/institutes/grid.422301.6",
"name": [
"Beatson West of Scotland Cancer Centre, Glasgow, UK"
],
"type": "Organization"
},
"familyName": "Sweeting",
"givenName": "Lorna",
"id": "sg:person.0752677326.57",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752677326.57"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Newcastle University",
"id": "https://www.grid.ac/institutes/grid.1006.7",
"name": [
"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"
],
"type": "Organization"
},
"familyName": "Greystoke",
"givenName": "Alastair",
"id": "sg:person.0773547677.71",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773547677.71"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Christie Hospital NHS Foundation Trust",
"id": "https://www.grid.ac/institutes/grid.412917.8",
"name": [
"The Christie NHS Foundation Trust, Manchester, UK"
],
"type": "Organization"
},
"familyName": "Barriuso",
"givenName": "Jorge",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University College London",
"id": "https://www.grid.ac/institutes/grid.83440.3b",
"name": [
"UCL Cancer Institute, London, UK"
],
"type": "Organization"
},
"familyName": "Kristeleit",
"givenName": "Rebecca",
"id": "sg:person.01140351721.10",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140351721.10"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.4137/bcbcr.s29421",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1000921905"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10549-014-3144-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1002219105",
"https://doi.org/10.1007/s10549-014-3144-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10549-014-3144-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1002219105",
"https://doi.org/10.1007/s10549-014-3144-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12012-007-0014-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1004235755",
"https://doi.org/10.1007/s12012-007-0014-4"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2013.52.4892",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006959677"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.ijpharm.2013.01.010",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007082291"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.jchromb.2008.09.013",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011041981"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(15)01283-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014338125"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1078-0432.ccr-14-3252",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015500441"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10637-016-0418-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1020367645",
"https://doi.org/10.1007/s10637-016-0418-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10637-016-0418-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1020367645",
"https://doi.org/10.1007/s10637-016-0418-8"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1078-0432.ccr-09-0360",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024546443"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(11)60070-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025413289"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.ejca.2008.10.026",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1026558254"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00280-015-2868-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028528026",
"https://doi.org/10.1007/s00280-015-2868-7"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1535-7163.mct-08-0095",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1029470846"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrc1958",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035719328",
"https://doi.org/10.1038/nrc1958"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrc1958",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035719328",
"https://doi.org/10.1038/nrc1958"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.bcp.2010.04.020",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042899186"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1535-7163.mct-04-0345",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043330423"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00280-015-2878-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043428451",
"https://doi.org/10.1007/s00280-015-2878-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00280-015-2878-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043428451",
"https://doi.org/10.1007/s00280-015-2878-5"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3389/fphar.2015.00286",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043813505"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/bi901810u",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1055210409"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/bi901810u",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1055210409"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1079256316",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1082752385",
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2016.70.8297",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1084253732"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3390/pharmaceutics9020012",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1084436901"
],
"type": "CreativeWork"
}
],
"datePublished": "2019-02",
"datePublishedReg": "2019-02-01",
"description": "BACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours.\nMETHODS: Eligible patients with ECOG PS 0-1 were treated with eribulin-LF either on day 1 every 21 days (Schedule 1), or on days 1 and 15 every 28 days (Schedule 2). Doses ranged from 1.0 to 3.5\u2009mg/m2, with dose escalation in a 3\u2009+\u20093 design. The dose-expansion phase evaluated eribulin-LF in select tumour types.\nPRIMARY OBJECTIVES: maximum tolerated dose (MTD) and the recommended dose/schedule of eribulin-LF.\nRESULTS: Totally, 58 patients were enroled (median age\u2009=\u200962 years). The MTD was 1.4\u2009mg/m2 (Schedule 1) or 1.5\u2009mg/m2 (Schedule 2), the latter dose selected for the dose-expansion phase. Dose-limiting toxicity (DLTs) in Schedule 1: hypophosphatemia and increased transaminase levels. DLTs in Schedule 2: stomatitis, increased alanine aminotransferase, neutropenia and febrile neutropenia. The pharmacokinetic profile of eribulin-LF showed a similar half-life to that of eribulin (~30\u2009h), but with a 5-fold greater maximum serum concentration and a 40-fold greater area-under-the-curve. Eribulin-LF demonstrated clinical activity with approximately 10% of patients in both schedules achieving partial responses.\nCONCLUSIONS: Eribulin-LF was well tolerated with a favourable pharmacokinetic profile. Preliminary evidence of clinical activity in solid tumours was observed.",
"genre": "research_article",
"id": "sg:pub.10.1038/s41416-019-0377-x",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1017082",
"issn": [
"0007-0920",
"1532-1827"
],
"name": "British Journal of Cancer",
"type": "Periodical"
},
{
"issueNumber": "4",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "120"
}
],
"name": "Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours",
"pagination": "379-386",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"65fd9077ede18e0759c6b4aec765d190c6b68d83c488b2c1eb7755da21557f23"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"30679780"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"0370635"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/s41416-019-0377-x"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1111642723"
]
}
],
"sameAs": [
"https://doi.org/10.1038/s41416-019-0377-x",
"https://app.dimensions.ai/details/publication/pub.1111642723"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T09:10",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000338_0000000338/records_47967_00000002.jsonl",
"type": "ScholarlyArticle",
"url": "https://www.nature.com/articles/s41416-019-0377-x"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0377-x'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0377-x'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0377-x'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0377-x'
This table displays all metadata directly associated to this object as RDF triples.
257 TRIPLES
21 PREDICATES
53 URIs
21 LITERALS
9 BLANK NODES